Литература
1. Чаулин А.М., Дупляков Д.В. PCSK-9: современные представления о биологической роли и возможности использования в качестве диагностического маркера сердечно-сосудистых заболеваний. Часть 1 // Кардиология: новости, мнения, обучение. 2019. Т. 7, № 2. С. 45-57.
URL: https://cyberleninka.ru/article/n/pcsk-9-sovremennye-predstavleniya-o-biologicheskoy-roli-i-vozmozhnosti-ispolzovaniya-v-kachestve-diagnosticheskogo-markera-serdechno/viewer
2. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz J. et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration // Hepatology. 2008. Vol. 48, N 2. P. 646-654. URL: https://www.ncbi.nlm.nih.gov/pubmed/18666258. doi: 10.1002/hep.22354
3. McNutt M.C., Kwon H.J., Chen C., Chen J.R. et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression inHepG2 cells // J. Biol. Chem. 2009. Vol. 284, № 16. P. 10 56110 570. URL: https://www.ncbi.nlm.nih.gov/pubmed/19224862. doi: 10.1074/jbc.M808802200
4. Langhi C., Le May C., Gmyr V. et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion // Biochem. Biophys. Res. Commun. 2009. Vol. 390, N 4. P. 1288-1293. URL: https://www.ncbi.nlm.nih.gov/pubmed/19878649. doi: 10.1016/j.bbrc.2009.10.138
5. Le May C., Kourimate S., Langhi C. et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial tri-glyceridemia // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29, N 5. P. 684-690. URL: https://www.ncbi.nlm.nih.gov/pubmed/19265033. doi: 10.1161/ATVBAHA.108.181586
6. Lagace T.A., Curtis D.E., Garuti R. et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice // J. Clin. Invest. 2006. Vol. 116, N 11. P. 2995-3005. URL: https://www.ncbi.nlm.nih.gov/pubmed/17080197. doi: 10.1172/JCI29383
7. Grefhorst A., McNutt M.C., Lagace T.A., Horton J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice // J. Lipid Res. 2008. Vol. 49, N 6. P. 1303-1311. URL: https://www.ncbi.nlm.nih.gov/pubmed/18354138. doi: 10.1194/jlr.M800027-JLR200
8. Schmidt R.J., Beyer T.P., Bensch W.R. et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo // Biochem. Biophys. Res. Commun. 2008. Vol. 370, N 4. P. 634-640. URL: https://www.ncbi.nlm.nih.gov/pubmed/18406350. doi: 10.1016/j.bbrc.2008.04.004
9. Persson L., Cao G., Stahle L. et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30, N 12. P. 2666-2672. URL: https://www.ncbi.nlm.nih.gov/pubmed/20884874. doi: 10.1161/ATVBAHA.110.214130
10. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans // J. Lipid Res. 2010. Vol. 51, N 11. P. 3359-3363. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952577/. doi: 10.1194/jlr.P009860
11. Lakoski S.G., Lagace T.A., Cohen J.C. et al. Genetic and metabolic determinants of plasma PCSK9 levels // J. Clin. Endocrinol. Metab. 2009. Vol. 94, N 7. P. 2537-2543. URL: https://www.ncbi.nlm.nih.gov/pubmed/19351729. doi: 10.1210/jc.2009-0141
12. Persson L., Galman C., Angelin B., Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors // Endocrinology. 2009. Vol. 150, N 3. P. 1140-1146. URL: https://www.ncbi.nlm.nih.gov/pubmed/19008317. doi: 10.1210/en.2008-1281
13. Baass A., Dubuc G., Tremblay M. et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents // Clin. Chem. 2009. Vol. 55, N 9. P. 1637-1645. URL: https://academic.oup.com/clinchem/article/55/9/1637/5629167. doi: 10.1373/clinchem.2009.126987
14. Li S., Xu R.X., Guo Y.L. et al. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9 // Nutr. Metab. Cardiovasc. Dis. 2015. Vol. 25, N 4. P. 411-417. URL: https://pubmed.ncbi.nlm.nih.gov/25466598-abo-blood-group-in-relation-to-plasma-lipids-and-proprotein-convertase-subtilisinkexin-type-9/. doi: 10.1016/j.numecd.2014.10.015
15. Garrison R.J., Havlik R.J., Harris R.B. et al. ABO blood group and cardiovacular disease: the Framingham study // Atherosclerosis. 1976. Vol. 25, N 2-3. P. 311-318. URL: https://pubmed.ncbi.nlm.nih.gov/1008914-abo-blood-group-and-cardiovacular-disease-the-framingham-study/. doi: 10.1016/0021-9150(76)90036-8
16. Carpeggiani C., Coceani M., Landi P. et al. ABO blood group alleles: a risk factor for coronary artery disease. An angiographic study // Atherosclerosis. 2010. Vol. 211, N 2. P. 461-466. URL: https://pubmed.ncbi.nlm.nih.gov/20371059-abo-blood-group-alleles-a-risk-factor-for-coronary-artery-disease-an-angiographic-study/. doi: 10.1016/j.atherosclerosis.2010.03.012
17. Silbernagel G., Chapman M.J., Genser B. et al. High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis // J. Am. Coll. Cardiol. 2013. Vol. 62, N 4. P. 291-299. URL: https://pubmed.ncbi.nlm.nih.gov/. doi: 10.1016/j.jacc.2013.01.100
18. Zhang H., Mooney C.J., Reilly M.P. ABO blood groups and cardiovascular diseases // Int.J. Vasc. Med. 2012. Vol. 2012. Article ID 641917. URL: https://pubmed.ncbi.nlm.nih.gov/23133757-abo-blood-groups-and-cardiovascular-diseases/. doi: 10.1155/2012/641917
19. Paterson A.D., Lopes-Virella M.F., Waggott D. et al. Genomewide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29, N 11. P. 1958-1967. URL: https://pubmed.ncbi.nlm.nih.gov/. doi: 10.1161/ATVBAHA.109.192971
20. Li S., Guo Y.L., Xu R.X. et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease // Atherosclerosis. 2014. Vol. 234, N 2. P. 441-445. URL: https://pubmed.ncbi.nlm.nih.gov/. doi: 10.1016/j.atherosclerosis.2014.04.001
21. He M., Wolpin B., Rexrode K. et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies // Arterioscler. Thromb. Vasc. Biol. 2012. Vol. 32, N 3. P. 2314-2320. URL: https://pubmed.ncbi.nlm.nih.gov/22895671-abo-blood-group-and-risk-of-coronary-heart-disease-in-two-prospective-cohort-studies/. doi: 10.1161/ATVBAHA.112.248757
22. Cui Q., Ju X., Yang T. et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population // Atherosclerosis. 2010. Vol. 213, N 2. P. 632-636. URL: https://pubmed.ncbi.nlm.nih.gov/21040917-serum-pcsk9-is-associated-with-multiple-metabolic-factors-in-a-large-han-chinese-population/. doi: 10.1016/j.atherosclerosis.2010.09.027
23. Mayne J., Raymond A., Chaplin A., Cousins M. et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women // Biochem. Biophys. Res. Commun. 2007. Vol. 361, N 2. P. 451-456. URL: https://pubmed.ncbi.nlm.nih.gov/17645871-plasma-pcsk9-levels-correlate-with-cholesterol-in-men-but-not-in-women/. doi: 10.1016/j.bbrc.2007.07.029
24. Alborn W.E., Cao G., Careskey H.E. et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol // Clin. Chem. 2007. Vol. 53, N 10. P. 1814-1819. URL: https://academic.oup.com/clinchem/article/53/10/1814/5627210. doi: 10.1373/clinchem.2007.091280
25. Lambert G., Ancellin N., Charlton F. et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment // Clin. Chem. 2008. Vol. 54, N 6. P. 1038-1045. URL: https://pubmed.ncbi.nlm.nih.gov/18436719-plasma-pcsk9-concentrations-correlate-with-ldl-and-total-cholesterol-in-diabetic-patients-and-are-decreased-by-fenofibrate-treatment/. doi: 10.1373/clinchem.2007.099747
26. Dubuc G., Tremblay M., Pare G. et al. A new method for measurement of total plasma PCSK9: clinical applications // J. Lipid Res. 2010. Vol. 51, N 1. P. 140-149. URL: https://pubmed.ncbi.nlm.nih.gov/19571328-a-new-method-for-measurement-of-total-plasma-pcsk9-clinical-applications/. doi: 10.1194/jlr.M900273-JLR200
27. Furuhashi M., Omori A., Matsumoto M. et al. Independent link between levels of proprotein convertase subtilisin/kexin type 9 and FABP4 in a general population without medication // Am.J. Cardiol. 2016. Vol. 118, N 2. P. 198-203. URL: https://pubmed.ncbi.nlm.nih.gov/27241838-independent-link-between-levels-of-proprotein-convertase-subtilisinkexin-type-9-and-fabp4-in-a-general-population-without-medication/. doi: 10.1016/j.amjcard.2016.04.037
28. Мешков А.Н., Калинина М.В., Ершова А.И., и др. Уровень PCSK9 в семьях пациентов с семейной гиперхолестеринемией // Атеросклероз и дислипидемии. 2012. № 1. С. 12-15.
29. Рагино Ю.И., Астракова К.С., Шахтшнейдер Е.В. и др. Уровни в крови про-протеиновой конвертазы субтилизин-кексинового типа 9 (PCSK9) при гипер- и гипохолестеринемии // Атеросклероз и дислипидемии. 2015. № 4. С. 15-19.
30. Ежов М.В., Сергиенко И.В., Дупляков Д.В. и др. Результаты Российской научно-исследовательской программы по диагностике и лечению больных семейной гиперхолестеринемией. Высокая распространенность, низкая информированность, плохая приверженность // Атеросклероз и дислипидемии. 2017. № 2. С. 5-15.
31. Попова А.Б., Балахонова Т.В., Погорелова О.А. и др. Взаимосвязь уровня пропротеинконвертазы субтилизин/кексин 9-го типа с выраженностью атеросклероза сонных артерий у пациентов с гиперлипидемией // Атеросклероз и дислипидемии. 2016. № 2 (23). С. 33-40. URL: https://cyberleninka.ru/article/n/vzaimosvyaz-urovnya-proproteinkonvertazy-subtilizin-keksin-9-go-tipa-s-vyrazhennostyu-ateroskleroza-sonnyh-arteriy-u-patsientov-s/viewer
32. Ежов М.В., Близнюк С.А., Тмоян Н А. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС) // Рос. кардиол. журн. 2019. Т. 24, № 5. С. 7-13. URL: https://cyberleninka.ru/article/n/registr-patsientov-s-semeynoy-giperholesterinemiey-i-patsientov-ochen-vysokogo-serdechno-sosudistogo-riska-s-nedostatochnoy/viewer. doi: 10.15829/1560-4071-2019-5-7-13
33. Rashid S., Curtis D.E., Garuti R. et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 // Proc. Natl Acad. Sci. USA 2005. Vol. 102, N 15. P. 5374 - 5379. URL: https://pubmed.ncbi.nlm.nih.gov/15805190-decreased-plasma-cholesterol-and-hypersensitivity-to-statins-in-mice-lacking-pcsk9/. doi: 10.1073/pnas.0501652102
34. Dubuc G., Chamberland A., Wassef H. et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24, N 8. P. 1454-1459. URL: https://pubmed.ncbi.nlm.nih.gov/. doi: 10.1161/01.ATV.0000134621.14315.43
35. Careskey H.E., Davis R.A., Alborn W.E. et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 // J. Lipid Res. 2008. Vol. 49, N 2. P 394-398. URL: https://pubmed.ncbi.nlm.nih.gov/18033751-atorvastatin-increases-human-serum-levels-of-proprotein-convertase-subtilisinkexin-type-9/. doi: 10.1194/jlr.M700437-JLR200
36. Costet P., Hoffmann M.M., Cariou B. et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients // Atherosclerosis. 2010. Vol. 212, N 1. P 246-251. URL: https://www.sciencedirect.com/science/article/abs/pii/S0021915010004053. doi: 10.1016/j.atherosclerosis.2010.05.027
37. Welder G., Zineh I., Pacanowski M.A., Troutt J.S. et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol // J. Lipid Res. 2010. Vol. 51, N 9. P 2714-2721. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918453/. doi: 10.1194/jlr.M008144
38. Lakoski S.G., Xu F., Vega G.L. et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin // J. Clin. Endocrinol. Metab. 2010. Vol. 95, N 2. P. 800-809. URL: https://pubmed.ncbi.nlm.nih.gov/19965915-indices-of-cholesterol-metabolism-and-relative-responsiveness-to-ezetimibe-and-simvastatin/. doi: 10.1210/jc.2009-1952
39. Cariou B., Ouguerram K., Zair Y. et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypo-betalipoproteinemia // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29, N 12. P. 2191-2197. URL: https://pubmed.ncbi.nlm.nih.gov/19762784-pcsk9-dominant-negative-mutant-results-in-increased-ldl-catabolic-rate-and-familial-hypobetalipoproteinemia/. doi: 10.1161/ATVBAHA.109.194191
40. Sahebkar A., Simental-Mendia L.E., Guerrero-Romero F. et al. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials // Diabetes Obes. Metab. 2015. Vol. 17, N 11. P. 10421055. URL: https://pubmed.ncbi.nlm.nih.gov/26183252-effect-of-statin-therapy-on-plasma-proprotein-convertase-subtilisin-kexin-9-pcsk9-concentrations-a-systematic-review-and-meta-analysis-of-clinical-trials/. doi: 10.1111/dom.12536
41. Kourimate S., Le May C., Langhi C. et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/ kexin type 9 // J. Biol. Chem. 2008. Vol. 283, N 15. P. 9666-9673. URL: http://www.jbc.org/content/283/15/9666.full.html. doi: 10.1074/jbc.M705831200
42. Lambert G., Jarnoux A.L., Pineau T. et al. Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr // Endocrinology. 2006. Vol. 147, N 10. P. 4985-4995. URL: https://pubmed.ncbi.nlm.nih.gov/. doi: 10.1210/en.2006-0098
43. Mayne J., Dewpura T., Raymond A., Cousins M. et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans // Lipids Health Dis. 2008. Vol. 7. P. 22. URL: https://pubmed.ncbi.nlm.nih.gov/18547436-plasma-pcsk9-levels-are-significantly-modified-by-statins-and-fibrates-in-humans/. doi: 10.1186/1476-511X-7-22
44. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels // J. Lipid Res. 2009. Vol. 51, N 2. P. 345-351. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803236/. doi: 10.1194/jlr.M000620
45. Keith D.S., Nichols G.A., Gullion C.M. et al. Longitudinal foolow-up and outcomes among a population with chronic kidney disease in a large managed care organization // Arch. Intern. Med. 2004. Vol. 164, N 6. P. 659-663. URL: https://pubmed.ncbi.nlm.nih.gov/15037495-longitudinal-follow-up-and-outcomes-among-a-population-with-chronic-kidney-disease-in-a-large-managed-care-organization/. doi: 10.1001/archinte.164.6.659
46. Marino A., Tannock R.L. Role of dyslipidemia in patients with chronic kidney disease // Postgrad. Med. 2013. Vol. 125, N 4. P. 28-37. URL: https://pubmed.ncbi.nlm.nih.gov/23842535-role-of-dyslipidemia-in-patients-with-chronic-kidney-disease/. doi: 10.3810/pgm.2013.07.2676
47. Konarzewski M., Szolkiewicz M., Sucajtys-Szulc E. et al. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy // Am.J. Nephrol. 2014. Vol. 40, N 2. P. 157-163. URL: https://pubmed.ncbi.nlm.nih.gov/25171595-elevated-circulating-pcsk-9-concentration-in-renal-failure-patients-is-corrected-by-renal-replacement-therapy/. doi: 10.1159/000365935
48. Jin K., Park B.S., Kim Y.W., Vaziri N.D. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study // Am.J. Kidney Dis. 2014. Vol. 63, N 4. P. 584-589. URL: https://pubmed.ncbi.nlm.nih.gov/24315769-plasma-pcsk9-in-nephrotic-syndrome-and-in-peritoneal-dialysis-a-cross-sectional-study/. doi: 10.1053/j.ajkd.2013.10.042
49. Abujrad H., Mayne J., Ruzicka M. et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels // Atherosclerosis. 2014. Vol. 233, N 1. P. 123-129. URL: https://www.atherosclerosis-journal.com/article/S0021-9150(13)00783-1/abstract. doi: 10.1016/j.atherosclerosis.2013.12.030
50. Morena M., Le May C., Chenine L. et al. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism // J. Clin. Lipidol. 2017. Vol. 11, N 1. P. 87-93. URL: https://pubmed.ncbi.nlm.nih.gov/28391915-plasma-pcsk9-concentrations-during-the-course-of-nondiabetic-chronic-kidney-disease-relationship-with-glomerular-filtration-rate-and-lipid-metabolism/. doi: 10.1016/j.jacl.2016.10.005
51. Rogacev K.S., Heine G.N., Silbernagel G. et al. PCSK9 plasma concentrations are independent of GFR and do not predict cardiovascular events in patients with decreased GFR // PLoS One. 2016. Vol. 11, N 1. Article ID e0146920. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146920. doi: 10.1371/journal.pone.0146920
52. Niesen M., Bedi M., Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver // Arch. Biochem. Biophys. 2008. Vol. 470, N 2. P. 111-115. URL: https://pubmed.ncbi.nlm.nih.gov/18054320-diabetes-alters-ldl-receptor-and-pcsk9-expression-in-rat-liver/. doi: 10.1016/j.abb.2007.11.009
53. Mbikay M., Sirois F., Mayne J. et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities // FEBS Lett. 2010. Vol. 584, N 4. P. 701-706. URL: https://pubmed.ncbi.nlm.nih.gov/20026049-pcsk9-deficient-mice-exhibit-impaired-glucose-tolerance-and-pancreatic-islet-abnormalities/. doi: 10.1016/j.febslet.2009.12.018
54. Павлова Т.В., Дупляков Д.В., Воронцова С.А., Гусева ГН. Перспективы ведения пациентов со стабильным течением атеросклероза // Кардиология: новости, мнения, обучение. 2018. Т. 6, № 2. С. 9-14. URL: https://cyberleninka.ru/article/n/perspektivy-vedeniya-patsientov-so-stabilnym-techeniem-ateroskleroza/viewer. doi: 10.24411/2309-1908-2018-12001
55. Чаулин А.М., Мазаев А.Ю., Александров А.Г. Роль пропротеин конвертазы субтилизин/кексин типа 9 (PCSK-9) в метаболизме холестерина и новые возможности липидкорригующей терапии // Международный научно-исследовательский журнал. 2019. № 4-1 (82). С. 124-126. URL: https://research-journal.org/wp-content/uploads/2019/04/4-1-82.pdf#page=124. doi: 10.23670/IRJ.2019.82.4.025
56. Miao J., Manthena P.V., Haas M.E. et al. Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9 // Arterioscler. Thromb. Vasc. Biol. 2015. Vol. 35, N 7. P. 1589-1596. URL: https://pubmed.ncbi.nlm.nih.gov/26023080-role-of-insulin-in-the-regulation-of-proprotein-convertase-subtilisinkexin-type-9/. doi: 10.1161/ATVBAHA.115.305688
57. Cariou B., Le Bras M., Langhi C. et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients // Atherosclerosis 2010. Vol. 211, N 2. P. 700-702. URL: https://pubmed.ncbi.nlm.nih.gov/20452593-association-between-plasma-pcsk9-and-gamma-glutamyl-transferase-levels-in-diabetic-patients/. doi: 10.1016/j.atherosclerosis.2010.04.015
58. Paolicchi A., Emdin M., Passino C. et al. Beta-Lipoprotein and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis // Atherosclerosis 2006. Vol. 186, N 1. P. 80-85. URL: https://pubmed.ncbi.nlm.nih.gov/16112119-beta-lipoprotein-and-ldl-associated-serum-gamma-glutamyltransferase-in-patients-with-coronary-atherosclerosis/. doi: 10.1016/j.atherosclerosis.2005.07.012
59. Coue M., Barquissau V., Morigny P. et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes // Sci. Rep. 2018. Vol. 8, N 1. P. 1097. URL: https://pubmed.ncbi.nlm.nih.gov/29348496-natriuretic-peptides-promote-glucose-uptake-in-a-cgmp-dependent-manner-in-human-adipocytes/. doi: 10.1038/s41598-018-19619-0
60. Spannella F., Giulietti F., Cocci G. et al. N-terminal pro B-type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly // Nutr. Metab. Cardiovasc. Dis. 2018. Vol. 28, N 6. P. 629-635. URL: https://moh-it.pure.elsevier.com/en/publications/n-terminal-pro-b-type-natriuretic-peptide-is-inversely-correlated. doi: 10.1016/j.numecd.2018.02.013
61. Bordicchia M., Spannella F., Ferretti G. et al. PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides // Int.J. Mol. Sci. 2019. Vol. 20, N 2. P. 245. URL: https://pubmed.ncbi.nlm.nih.gov/30634533-pcsk9-is-expressed-in-human-visceral-adipose-tissue-and-regulated-by-insulin-and-cardiac-natriuretic-peptides/. doi: 10.3390/ijms20020245
62. Gong Y., Ma Y., Ye Z. et al. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulation hepatic PCSK9 expression // Metabolism. 2017. Vol. 76. P. 32-41. URL: https://pubmed.ncbi.nlm.nih.gov/28987238-thyroid-stimulating-hormone-exhibits-the-impact-on-ldlrldl-c-via-up-regulating-hepatic-pcsk9-expression/. doi: 10.1016/j.metabol.2017.07.006
63. Almontashiri N.A., Vilmundarson R.O., Ghasemzadeh N. et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies // PLoS One. 2014. Vol. 9, N 9. Article ID e106294. URL: https://pubmed.ncbi.nlm.nih.gov/25180781-plasma-pcsk9-levels-are-elevated-with-acute-myocardial-infarction-in-two-independent-retrospective-angiographic-studies/. doi: 10.1371/journal.pone.0106294
64. Cariou B., Guerin P., Le Mayc C. et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study // Diabetes Metab. 2017. Vol. 43, N 6. P. 529-535. URL: https://pubmed.ncbi.nlm.nih.gov/28865748-circulating-pcsk9-levels-in-acute-coronary-syndrome-results-from-the-pc-sca-9-prospective-study/. doi: 10.1016/j.diabet.2017.07.009
65. Bae K.H., Kim S.W., Choi Y.K. et al. Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome // Diabetes Metab J. 2018. Vol. 42, N 3. P. 207214. URL: https://pubmed.ncbi.nlm.nih.gov/29885102-serum-levels-of-pcsk9-are-associated-with-coronary-angiographic-severity-in-patients-with-acute-coronary-syndrome/. doi: 10.4093/dmj.2017.0081
66. Toth S., Fedacko J., Pekarova T. et al. Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic changes in low risk obese and non-obese patients // Cardiol. Ther. 2017. Vol. 6, N 2. P. 281-289. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688969/. doi: 10.1007/s40119-017-0092-8
References
1. Chaulin A.M., Duplyakov D.V. PCSK-9: modern views about biological role and possibilities of use as a diagnostic marker for cardiovascular diseases. Part 1. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2019; 7 (2): 45-57. doi: 10.24411/2309-1908-2019-12005. (in Russian) URL: https://cyberleninka.ru/article/n/pcsk-9-sovremennye-predstavleniya-o-biologicheskoy-roli-i-vozmozhnosti-ispolzovaniya-v-kachestve-diagnosticheskogo-markera-serdechno/viewer
2. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz J., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008; 48 (2): 646-54. URL: https://www.ncbi.nlm.nih.gov/pubmed/18666258. doi: 10.1002/hep.22354
3. McNutt M.C., Kwon H.J., Chen C., Chen J.R., et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression inHepG2 cells. J Biol Chem. 2009; 284 (16): 10 561-70. URL: https://www.ncbi.nlm.nih.gov/pubmed/19224862. doi: 10.1074/jbc.M808802200
4. Langhi C., Le May C., Gmyr V., et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009; 390 (4): 1288-93. URL: https://www.ncbi.nlm.nih.gov/pubmed/19878649. doi: 10.1016/j.bbrc.2009.10.138
5. Le May C., Kourimate S., Langhi C., et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009; 29 (5): 684-690. URL: https://www.ncbi.nlm.nih.gov/pubmed/19265033. doi: 10.1161/ATVBAHA.108.181586
6. Lagace T.A., Curtis D.E., Garuti R., et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J Clin Invest. 2006; 116 (11): 29953005. URL: https://www.ncbi.nlm.nih.gov/pubmed/17080197. doi: 10.1172/JCI29383
7. Grefhorst A., McNutt M.C., Lagace T.A., Horton J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008; 49 (6): 1303-11. URL: https://www.ncbi.nlm.nih.gov/pubmed/18354138. doi: 10.1194/jlr.M800027-JLR200
8. Schmidt R.J., Beyer T.P., Bensch W.R., et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun. 2008; 370 (4): 634-40. URL: https://www.ncbi.nlm.nih.gov/pubmed/18406350. doi: 10.1016/j.bbrc.2008.04.004
9. Persson L., Cao G., Stahle L., et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010; 30 (12): 2666-72. URL: https://www.ncbi.nlm.nih.gov/pubmed/20884874. doi: 10.1161/ATVBAHA.110.214130
10. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res. 2010; 51 (11): 3359-63. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952577/. doi: 10.1194/jlr.P009860
11. Lakoski S.G., Lagace T.A., Cohen J.C., et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009; 94 (7): 2537-43. URL: https://www.ncbi.nlm.nih.gov/pubmed/19351729. doi: 10.1210/jc.2009-0141
12. Persson L., Galman C., Angelin B., Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology. 2009; 150 (3): 1140-6. URL: https://www.ncbi.nlm.nih.gov/pubmed/19008317. doi: 10.1210/en.2008-1281
13. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009; 55 (9): 1637-45. URL: https://academic.oup.com/clinchem/article/55/9/1637/5629167. doi: 10.1373/clinchem.2009.126987
14. Li S., Xu R.X., Guo Y.L., et al. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9. Nutr Metab Cardiovasc Dis. 2015; 25 (4): 411-7. URL: https://pubmed.ncbi.nlm.nih.gov/25466598-abo-blood-group-in-relation-to-plasma-lipids-and-proprotein-convertase-subtilisinkexin-type-9/. doi: 10.1016/j.numecd.2014.10.015
15. Garrison R.J., Havlik R.J., Harris R.B., et al. ABO blood group and cardiovacular disease: the Framingham study. Atherosclerosis. 1976; 25 (2-3): 311-8. URL: https://pubmed.ncbi.nlm.nih.gov/1008914-abo-blood-group-and-cardiovacular-disease-the-framingham-study/. doi: 10.1016/0021-9150(76)90036-8
16. Carpeggiani C., Coceani M., Landi P., et al. ABO blood group alleles: a risk factor for coronary artery disease. An angiographic study. Atherosclerosis. 2010; 211 (2): 461-6. URL: https://pubmed.ncbi.nlm.nih.gov/20371059-abo-blood-group-alleles-a-risk-factor-for-coronary-artery-disease-an-angiographic-study/. doi: 10.1016/j.atherosclerosis.2010.03.012
17. Silbernagel G., Chapman M.J., Genser B., et al. High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis. J Am Coll Cardiol. 2013; 62 (4): 291-9. URL: https://pubmed.ncbi.nlm.nih.gov/23707316-high-intestinal-cholesterol-absorption-is-associated-with-cardiovascular-disease-and-risk-alleles-in-abcg8-and-abo-evidence-from-the-luric-and-yfs-cohorts-and-from-a-meta-analysis/. doi: 10.1016/j.jacc.2013.01.100
18. Zhang H., Mooney C.J., Reilly M.P. ABO blood groups and cardiovascular diseases. Int J Vasc Med. 2012; 2012: 641917. URL: https://pubmed.ncbi.nlm.nih.gov/23133757-abo-blood-groups-and-cardiovascular-diseases/. doi: 10.1155/2012/641917
19. Paterson A.D., Lopes-Virella M.F., Waggott D., et al. Genomewide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009; 29 (11): 1958-67. URL: https://pubmed.ncbi.nlm.nih.gov/19729612-genome-wide-association-identifies-the-abo-blood-group-as-a-major-locus-associated-with-serum-levels-of-soluble-e-selectin/. doi: 10.1161/ATVBAHA.109.192971
20. Li S., Guo Y.L., Xu R.X., et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. 2014; 234 (2): 441-5. URL: https://pubmed.ncbi.nlm.nih.gov/24769476-association-of-plasma-pcsk9-levels-with-white-blood-cell-count-and-its-subsets-in-patients-with-stable-coronary-artery-disease/. doi: 10.1016/j.atherosclerosis.2014.04.001
21. He M., Wolpin B., Rexrode K., et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol. 2012; 32 (3): 2314-20. URL: https://pubmed.ncbi.nlm.nih.gov/22895671-abo-blood-group-and-risk-of-coronary-heart-disease-in-two-prospective-cohort-studies/. doi: 10.1161/ATVBAHA.112.248757
22. Cui Q., Ju X., Yang T., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010; 213 (2): 632-6. URL: https://pubmed.ncbi.nlm.nih.gov/21040917-serum-pcsk9-is-associated-with-multiple-metabolic-factors-in-a-large-han-chinese-population/. doi: 10.1016/j.atherosclerosis.2010.09.027
23. Mayne J., Raymond A., Chaplin A., Cousins M., et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun. 2007; 361 (2): 451-6. URL: https://pubmed.ncbi.nlm.nih.gov/17645871-plasma-pcsk9-levels-correlate-with-cholesterol-in-men-but-not-in-women/. doi: 10.1016/j.bbrc.2007.07.029
24. Alborn W.E., Cao G., Careskey H.E., et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007; 53 (10): 1814-9. URL: https://academic.oup.com/clinchem/article/53/10/1814/5627210. doi: 10.1373/clinchem.2007.091280
25. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem. 2008; 54 (6): 1038-45. URL: https://pubmed.ncbi.nlm.nih.gov/18436719-plasma-pcsk9-concentrations-correlate-with-ldl-and-total-cholesterol-in-diabetic-patients-and-are-decreased-by-fenofibrate-treatment/. doi: 10.1373/clinchem.2007.099747
26. Dubuc G., Tremblay M., Pare G., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010; 51 (1): 140-9. URL: https://pubmed.ncbi.nlm.nih.gov/19571328-a-new-method-for-measurement-of-total-plasma-pcsk9-clinical-applications/. doi: 10.1194/jlr.M900273-JLR200
27. Furuhashi M., Omori A., Matsumoto M., et al. Independent link between levels of proprotein convertase subtilisin/kexin type 9 and FABP4 in a general population without medication. Am J Cardiol. 2016; 118 (2): 198-203. URL: https://pubmed.ncbi.nlm.nih.gov/27241838-independent-link-between-levels-of-proprotein-convertase-subtilisinkexin-type-9-and-fabp4-in-a-general-population-without-medication/. doi: 10.1016/j.amjcard.2016.04.037
28. Meshkov A.N., Kalinina M.V., Ershova A.I., et al. The level of PCSK9 in patients with familial hypercholesterolemia. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2012; (1): 12-5.. (in Russian)
29. Ragino Yu.I., Astrakova K.S., Shakhtshneider E.V., et al. Blood levels of proprotein convertase subtilisin/kexin type (pcsk9) in hyper- and hypocholesterolemia. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2015; (4): 15-9. (in Russian)
30. Ezhov M.V., Sergienko I.V., Duplyakov D.V., et al. Results of the Russian research program on the diagnosis and treatment of patients with familial hypercholesterolemia. High prevalence, low awareness, poor adherence. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2017; (2): 5-15. (in Russian)
31. Popova A.B., Balahonova T.V., Pogorelova O.A., et al. The relationship level proprotein convertase subtilizin/kexin 9 type with the severity of carotid atherosclerosis in patients with hyperlipidemia. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2016; 2 (23): 33-40. (in Russian)
32. Yezhov M.V., Bliznyuk S.A., Tmoyan N.A., et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2019; (5): 7-13. (in Russian). URL: https://cyberleninka.ru/article/n/registr-patsientov-s-semeynoy-giperholesterinemiey-i-patsientov-ochen-vysokogo-serdechno-sosudistogo-riska-s-nedostatochnoy/viewer. doi: 10.15829/1560-4071-2019-5-7-13
33. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005; 102 (15): 5374 - 9. URL: https://pubmed.ncbi.nlm.nih.gov/15805190-decreased-plasma-cholesterol-and-hypersensitivity-to-statins-in-mice-lacking-pcsk9/. doi: 10.1073/pnas.0501652102
34. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24 (8): 1454-9. ATV.0000134621.14315.43. URL: https://pubmed.ncbi.nlm.nih.gov/. doi: 10.1161/01.ATV.0000134621.14315.43
35. Careskey H.E., Davis R.A., Alborn W.E., et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008; 49 (2): 394-8. URL: https://pubmed.ncbi.nlm.nih.gov/18033751-atorvastatin-increases-human-serum-levels-of-proprotein-convertase-subtilisinkexin-type-9/. doi: 10.1194/jlr.M700437-JLR200
36. Costet P., Hoffmann M.M., Cariou B., et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010; 212 (1): 246-51. URL: https://www.sciencedirect.com/science/article/abs/pii/S0021915010004053. doi: 10.1016/j.atherosclerosis.2010.05.027
37. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010; 51 (9): 2714-21. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918453/. doi: 10.1194/jlr.M008144
38. Lakoski S.G., Xu F., Vega G.L., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010; 95 (2): 800-9. URL: https://pubmed.ncbi.nlm.nih.gov/19965915-indices-of-cholesterol-metabolism-and-relative-responsiveness-to-ezetimibe-and-simvastatin/. doi: 10.1210/jc.2009-1952
39. Cariou B., Ouguerram K., Zair Y., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009: 29 (12): 2191-7. URL: https://pubmed.ncbi.nlm.nih.gov/19762784-pcsk9-dominant-negative-mutant-results-in-increased-ldl-catabolic-rate-and-familial-hypobetalipoproteinemia/. doi: 10.1161/ATVBAHA.109.194191
40. Sahebkar A., Simental-Mendia L.E., Guerrero-Romero F., et al. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes Obes Metab. 2015; 17 (11): 1042-55. URL: https://pubmed.ncbi.nlm.nih.gov/26183252. doi: 10.1111/dom.12536
41. Kourimate S., Le May C., Langhi C., et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/ kexin type 9. J Biol Chem. 2008; 283 (15): 9666-73. URL: http://www.jbc.org/content/283/15/9666.full.html. doi: 10.1074/jbc.M705831200
42. Lambert G., Jarnoux A.L., Pineau T., et al. Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology. 2006; 147 (10): 4985-95. URL: https://pubmed.ncbi.nlm.nih.gov/16794006. doi: 10.1210/en.2006-0098
43. Mayne J., Dewpura T., Raymond A., Cousins M., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008; 7: 22. URL: https://pubmed.ncbi.nlm.nih.gov/18547436-plasma-pcsk9-levels-are-significantly-modified-by-statins-and-fibrates-in-humans/. doi: 10.1186/1476-511X-7-22
44. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels. J Lipid Res. 2009; 51 (2): 345-51. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803236/. doi: 10.1194/jlr.M000620
45. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal foolow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164 (6): 659-63. URL: https://pubmed.ncbi.nlm.nih.gov/15037495-longitudinal-follow-up-and-outcomes-among-a-population-with-chronic-kidney-disease-in-a-large-managed-care-organization/. doi: 10.1001/archinte.164.6.659
46. Marino A., Tannock R.L. Role of dyslipidemia in patients with chronic kidney disease. Postgrad Med. 2013; 125 (4): 28-37. URL: https://pubmed.ncbi.nlm.nih.gov/23842535-role-of-dyslipidemia-in-patients-with-chronic-kidney-disease/. doi: 10.3810/pgm.2013.07.2676
47. Konarzewski M., Szolkiewicz M., Sucajtys-Szulc E., et al. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol 2014; 40 (2): 157-63. URL: https://pubmed.ncbi.nlm.nih.gov/25171595-elevated-circulating-pcsk-9-concentration-in-renal-failure-patients-is-corrected-by-renal-replacement-therapy/. doi: 10.1159/000365935
48. Jin K., Park B.S., Kim Y.W., Vaziri N.D. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014; 63 (4): 584-9. URL: https://pubmed.ncbi.nlm.nih.gov/24315769-plasma-pcsk9-in-nephrotic-syndrome-and-in-peritoneal-dialysis-a-cross-sectional-study/. doi: 10.1053/j.ajkd.2013.10.042
49. Abujrad H., Mayne J., Ruzicka M., et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 2014; 233 (1): 123-9. URL: https://www.atherosclerosis-journal.com/article/S0021-9150(13)00783-1/abstract. doi: 10.1016/j.atherosclerosis.2013.12.030
50. Morena M., Le May C., Chenine L., et al. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol. 2017; 11 (1): 87-93. URL: https://pubmed.ncbi.nlm.nih.gov/28391915. doi: 10.1016/j.jacl.2016.10.005
51. Rogacev K.S., Heine G.N., Silbernagel G., et al. PCSK9 plasma concentrations are independent of GFR and do not predict cardiovascular events in patients with decreased GFR. PLoS One. 2016; 11 (1): e0146920. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146920. doi: 10.1371/journal.pone.0146920
52. Niesen M., Bedi M., Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys. 2008; 470 (2): 111-5. URL: https://pubmed.ncbi.nlm.nih.gov/18054320-diabetes-alters-ldl-receptor-and-pcsk9-expression-in-rat-liver/. doi: 10.1016/j.abb.2007.11.009
53. Mbikay M., Sirois F., Mayne J., et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010; 584 (4): 701-6. URL: https://pubmed.ncbi.nlm.nih.gov/20026049-pcsk9-deficient-mice-exhibit-impaired-glucose-tolerance-and-pancreatic-islet-abnormalities/. doi: 10.1016/j.febslet.2009.12.018
54. Pavlova T.V., Duplyakov D.V., Vorontsova S.A., Guseva G.N. Prospects for managing patients with stable atherosclerosis. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2018; 6 (2): 9-14. doi: 10.24411/2309-1908-2018-12001. (in Russian). URL: https://cyberleninka.ru/article/n/perspektivy-vedeniya-patsientov-so-stabilnym-techeniem-ateroskleroza/viewer. doi: 10.24411/2309-1908-2018-12001
55. Chaulin A.M., Mazaev A.Yu., Aleksandrov A.G. The role of proprotein convertase subtilisin/kexin of type 9 (PCSK-9) in cholesterol metabolism and new opportunities of lipid corrective therapy. International Research Journal. 2019; 4-1 (82): 124-6. (in Russian). URL: https://research-journal.org/wp-content/uploads/2019/04/4-1-82.pdf#page=124. doi: 10.23670/IRJ.2019.82.4.025
56. Miao J., Manthena P.V., Haas M.E., et al. Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9. Arterio-scler Thromb Vasc Biol. 2015; 35 (7): 1589-96. URL: https://pubmed.ncbi.nlm.nih.gov/26023080-role-of-insulin-in-the-regulation-of-proprotein-convertase-subtilisinkexin-type-9/. doi: 10.1161/ATVBAHA.115.305688
57. Cariou B., Le Bras M., Langhi C., et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis. 2010; 211 (2): 700-2. URL: https://pubmed.ncbi.nlm.nih.gov/20452593-association-between-plasma-pcsk9-and-gamma-glutamyl-transferase-levels-in-diabetic-patients/. doi: 10.1016/j.atherosclerosis.2010.04.015
58. Paolicchi A., Emdin M., Passino C., et al. Beta-Lipoprotein and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006; 186 (1): 80-5. URL: https://pubmed.ncbi.nlm.nih.gov/16112119-beta. doi: 10.1016/j.atherosclerosis.2005.07.012
59. Coue M., Barquissau V., Morigny P., et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. Sci Rep. 2018; 8 (1): 1097.
URL: https://pubmed.ncbi.nlm.nih.gov/29348496-natriuretic-peptides-promote-glucose-uptake-in-a-cgmp-dependent-manner-in-human-adipocytes/. doi: 10.1038/s41598-018-19619-0
60. Spannella F., Giulietti F., Cocci G., et al. N-terminal pro B-type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly. Nutr Metab Cardiovasc Dis. 2018; 28 (6): 629-635. URL: https://moh-it.pure.elsevier.com/en/publications/n-terminal-pro-b-type-natriuretic-peptide-is-inversely-correlated. doi: 10.1016/j.numecd.2018.02.013
61. Bordicchia M., Spannella F., Ferretti G., et al. PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides. Int J Mol Sci. 2019; 20 (2): 245. URL: https://pubmed.ncbi.nlm.nih.gov/30634533-pcsk9-is-expressed-in-human-visceral-adipose-tissue-and-regulated-by-insulin-and-cardiac-natriuretic-peptides/. doi: 10.3390/ijms20020245
62. Gong Y., Ma Y., Ye Z., et al. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulation hepatic PCSK9 expression. Metabolism. 2017; 76: 32-41. URL: https://pubmed.ncbi.nlm.nih.gov/28987238-thyroid-stimulating-hormone-exhibits-the-impact-on-ldlrldl-c-via-up-regulating-hepatic-pcsk9-expression/. doi: 10.1016/j.metabol.2017.07.006
63. Almontashiri N.A., Vilmundarson R.O., Ghasemzadeh N., et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014; 9 (9): e106294. URL: https://pubmed.ncbi.nlm.nih.gov/25180781-plasma-pcsk9-levels-are-elevated-with-acute-myocardial-infarction-in-two-independent-retrospective-angiographic-studies/. doi: 10.1371/journal.pone.0106294
64. Cariou B., Guerin P., Le Mayc C., et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes Metab. 2017; 43 (6): 529-35. URL: https://pubmed.ncbi.nlm.nih.gov/28865748-circulating-pcsk9-levels-in-acute-coronary-syndrome-results-from-the-pc-sca-9-prospective-study/. doi: 10.1016/j.diabet.2017.07.009
65. Bae K.H., Kim S.W., Choi Y.K., et al. Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome // Diabetes Metab J. 2018; 42 (3): 207-14. URL: https://pubmed.ncbi.nlm.nih.gov/29885102-serum-levels-of-pcsk9-are-associated-with-coronary-angiographic-severity-in-patients-with-acute-coronary-syndrome/. doi: 10.4093/dmj.2017.0081
66. Toth S., Fedacko J., Pekarova T., et al. Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic changes in low risk obese and non-obese patients. Cardiol Ther. 2017; 6 (2): 2819. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688969/. doi: 10.1007/s40119-017-0092-8